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Cost-Effectiveness of Olanzapine as a First-Line Treatment: 
A Comment
To the Editor––Tunis et al. [1] present the results from
a randomized, open-label, 1-year trial that evaluates
the cost-effectiveness of olanzapine as ﬁrst-line
treatment versus a generic fail-ﬁrst regimen for schiz-
ophrenia. The authors must be congratulated for a
well-designed study and for a rigorous analysis of the
results. There are many interesting and important
results that are revealed by this analysis. Here, I would
like to raise an issue that is tied to the economic eval-
uations of a fail-ﬁrst design, which the authors do not
account for in their results and fail to discuss in their
conclusions.
The underlying economic rationale for the advan-
tage of an algorithm with generic ﬁrst-line treatment is
an implicit individualization mechanism that enables
patients, who beneﬁt from generic drugs and for whom
branded drugs do not offer any additional beneﬁts, to
stay on the generic drug. As expected, more patients
switch from their assigned therapy in the CON group
than in the olanzapine group [1]. Nevertheless, pa-
tients in the conventional antipsychotics group who do
not switch and continue to beneﬁt from the conven-
tional antipsychotics would represent a recurring cost-
saving for as long as they receive them. For example, in
Tunis et al.’s study [1], 31.4% of patients remain on
conventional antipsychotics till the end of the study
while 56.1% remain on olanzapine (ﬁgure 1 in Tunis
et al. [1]). If we assume that out of the 31.4% of
patients who presumably beneﬁted from conventional
drugs, at least 56.1% would have similarly beneﬁted
from olanzapine, then without a fail-ﬁrst regimen the
additional drug costs per patient can be estimated
conservatively  to  be  $367  (=0.314 × 0.561 × [3756
− 1652]). This translates to a 5-year cost-saving of
$1731 per patient at 3% discount rate associated with
a fail-ﬁrst regimen, without any signiﬁcant offset to
the effectiveness side. With generic second-generation
antipsychotics, these savings may be even more with
a fail-ﬁrst regimen. These savings may be enough to
substantially inﬂuence the results of cost-effectiveness
presented by Tunis et al. [1].
These issues suggest that the cost-effectiveness of a
generic fail-ﬁrst regimen evaluated over short duration
should be viewed and interpreted cautiously.––Anir-
ban Basu, PhD, Section of General Internal Medicine,
Department of Medicine, Center for Health and Social
Sciences, University of Chicago, and Decision and
Information Sciences Division, Argonne National Lab-
oratories, Chicago, IL, USA.
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